The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy

Kim,So  Y.; Kang,Sujin; Song,Jae  J.; Kim,Joo-Hang

doi:10.3892/ijo.2013.1812

The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy

Authors:
- So Y. Kim
- Sujin Kang
- Jae J. Song
- Joo-Hang Kim
View Affiliations

Affiliations: Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Republic of Korea, Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea
Published online on: February 7, 2013 https://doi.org/10.3892/ijo.2013.1812
Pages: 1337-1348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To overcome the poor tumor transduction efficiency of adenovirus serotype 5 (Ad5) observed in several types of cancer, the fiber region of Ad5, apart from its tail, was replaced by adenovirus serotype 35 (Ad35). The chimeric Ad5̸F35 adenoviral vector did not exhibit any significant enhancement of transduction efficiency. CD46, a receptor for Ad35, was expressed in relatively small amounts in most of the cancer cells examined. Therefore, we investigated the pivotal factor(s) that render cancer cells susceptible to transduction. We discovered that the tumor transduction efficiency of Ad5/F35 was enhanced in the presence of rapamycin, an autophagy inducer, in some cancer cells. Analysis of survival potential and cell proliferation rates revealed that Ad5/F35 exerted a more pronounced oncolytic effect in cancer cells with higher survival potential in the presence of rapamycin.

View Figures

View References

1	Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML and Naomoto Y: Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med. 25:3–10. 2010.PubMed/NCBI
2	Sharma A, Tandon M, Bangari DS and Mittal SK: Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther. 4:117–138. 2009. View Article : Google Scholar : PubMed/NCBI
3	Douglas JT: Adenoviral vectors for gene therapy. Mol Biotechnol. 36:71–80. 2007. View Article : Google Scholar : PubMed/NCBI
4	Russell SJ, Peng KW and Bell JC: Oncolytic virotherapy. Nature Biotech. 30:658–670. 2012. View Article : Google Scholar
5	Edukulla R, Woller N, Mundt B, et al: Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res. 69:1448–1458. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rux JJ and Burnett RM: Adenovirus structure. Hum Gene Ther. 15:1167–1176. 2004. View Article : Google Scholar : PubMed/NCBI
7	Burnett RM: The structure of the adenovirus capsid. II The packing symmetry of hexon and its implications for viral architecture. J Mol Biol. 185:125–143. 1985.PubMed/NCBI
8	Wickham TJ, Segal DM, Roelvink PW, et al: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 70:6831–6838. 1996.PubMed/NCBI
9	Stevenson SC, Rollence M, Marshall-Neff J and McClelland A: Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol. 71:4782–4790. 1997.PubMed/NCBI
10	Zabner J, Freimuth P, Puga A, Fabrega A and Welsh MJ: Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J Clin Invest. 100:1144–1149. 1997. View Article : Google Scholar : PubMed/NCBI
11	Chillon M, Bosch A, Zabner J, et al: Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol. 73:2537–2540. 1999.PubMed/NCBI
12	Tomko RP, Xu R and Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA. 94:3352–3356. 1997. View Article : Google Scholar : PubMed/NCBI
13	Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G and Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol. 74:2567–2583. 2000.
14	Wickham TJ, Tzeng E, Shears LL II, et al: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 71:8221–8229. 1997.PubMed/NCBI
15	Wickham TJ, Lee GM, Titus JA, et al: Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 71:7663–7669. 1997.PubMed/NCBI
16	Okada Y, Okada N, Nakagawa S, et al: Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett. 177:57–63. 2002. View Article : Google Scholar
17	Mizuguchi H and Hayakawa T: Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene. 285:69–77. 2002. View Article : Google Scholar : PubMed/NCBI
18	Joubert PE, Meiffren G, Grégoire IP, et al: Autophagy induction by the pathogen receptor CD46. Cell Host Microbe. 6:354–366. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hemmi S, Geertsen R, Mezzacasa A, Peter I and Dummer R: The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 9:2363–2373. 1998. View Article : Google Scholar
20	Toyoda E, Doi R, Kami K, et al: Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int J Oncol. 33:1141–1147. 2008.PubMed/NCBI
21	Yu L, Shimozato O, Li Q, et al: Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 27:2311–2316. 2007.PubMed/NCBI
22	Yu L, Takenobu H, Shimozato O, et al: Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep. 14:831–835. 2005.PubMed/NCBI
23	Rodriguez-Rocha H, Gomez-Gutierrez JG, Garcia-Garcia A, et al: Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology. 416:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
24	Abounit K, Scarabelli TM and McCauley RB: Autophagy in mammalian cells. World J Biol Chem. 3:1–6. 2012.
25	Noda T and Ohsumi Y: Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 273:3963–3966. 1998. View Article : Google Scholar : PubMed/NCBI
26	Asnaghi L, Bruno P, Priulla M and Nicolin A: mTOR: a protein kinase switching between life and death. Pharmacol Res. 50:545–549. 2004. View Article : Google Scholar : PubMed/NCBI
27	Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G and Nicolin A: Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer. 37:2121–2128. 2001. View Article : Google Scholar : PubMed/NCBI
28	Ravikumar B, Berger Z, Vacher C, O’Kane CJ and Rubinsztein DC: Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet. 15:1209–1216. 2006. View Article : Google Scholar : PubMed/NCBI
29	Everts B and van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12:141–161. 2005. View Article : Google Scholar : PubMed/NCBI
30	Guo ZS, Thorne SH and Bartlett DL: Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 1785:217–231. 2008.PubMed/NCBI
31	Wu L, Johnson M and Sato M: Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med. 9:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
32	Diepgen TL and Mahler V: The epidemiology of skin cancer. Br J Dermatol. 146(Suppl 61): 1–6. 2002. View Article : Google Scholar
33	Lu B, Makhija SK, Nettelbeck DM, et al: Evaluation of tumor-specific promoter activities in melanoma. Gene Ther. 12:330–338. 2005. View Article : Google Scholar : PubMed/NCBI
34	Yun CO, Cho EA, Song JJ, et al: dl-VSVG-LacZ, a vesicular stomatitis virus glycoprotein epitope-incorporated adenovirus, exhibits marked enhancement in gene transduction efficiency. Hum Gene Ther. 14:1643–1652. 2003. View Article : Google Scholar
35	Yun CO, Kim E, Koo T, Kim H, Lee YS and Kim JH: ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther. 12:61–71. 2005. View Article : Google Scholar : PubMed/NCBI
36	Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR and McNeish IA: Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene. 27:3081–3090. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ito H, Aoki H, Kühnel F, et al: Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 98:625–636. 2006. View Article : Google Scholar : PubMed/NCBI
38	Jiang H, Gomez-Manzano C, Aoki H, et al: Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 99:1410–1414. 2007. View Article : Google Scholar : PubMed/NCBI
39	Jiang H, White EJ, Gomez-Manzano C and Fueyo J: Adenovirus’s last trick: you say lysis, we say autophagy. Autophagy. 4:118–120. 2008.
40	Wu YT, Tan HL, Shui G, et al: Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 285:10850–10861. 2010. View Article : Google Scholar : PubMed/NCBI
41	Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H and Lieber A: The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol. 77:3712–3723. 2003. View Article : Google Scholar